Status and phase
Conditions
Treatments
About
This study is a multicentre, randomized controlled trial of ivabradine versus placebo.
Full description
The PREVENT-MINS study is a 2,500 patient multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective of the trial is to determine the impact of ivabradine versus placebo on the risk of MINS in patients with or at risk of atherosclerotic disease who are followed for 30 days after noncardiac surgery.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A. History of coronary artery disease B. History of peripheral arterial disease C. History of stroke D. Undergoing major vascular surgery, OR
E. Any 3 of 9 risk criteria:
i. Undergoing major surgery ii. History of congestive heart failure iii. History of a transient ischaemic attack iv. Diabetes and currently taking an oral hypoglycemic agent or insulin v. Age ≥70 years vi. History of hypertension vii. Serum creatinine >175 µmol/L (>2.0 mg/dl) viii. History of smoking within 2 years of surgery ix. Undergoing emergent/urgent surgery
Exclusion criteria
Conduction abnormalities:
A. Non-sinus rhythm on ECG B. Sinoatrial or AV (2nd and 3d degree) blocks C. Sick sinus syndrome D. Long QT syndrome E. Pacemaker dependent
Transplanted heart (or on waiting list)
Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
Resting heart rate <65 beats per minute on the day of surgery
Systolic blood pressure <90 mmHg on the day of surgery
Acute decompensated heart failure, cardiogenic shock, acute myocarditis
Acute coronary syndrome within 2 months before surgery;
Stroke or transient cerebral ischaemia within 1 month before surgery
Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min)
Inability to tolerate oral intake
Recent use of ivabradine (<1 month)
Known allergy or hypersensitivity to ivabradine
Low-risk surgical procedure based on individual physician's judgment
Investigator considers the patient unreliable regarding requirement for study compliance
Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
Previously enrolled in the PREVENT-MINS study
Primary purpose
Allocation
Interventional model
Masking
2,500 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Eliza Kłosowska-Przybył; Bożena Seczyńska, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal